WITHOUT PATENTS, BIOPHARMA COMPANIES CANNOT GET FUNDING. Without the significant amount of work needed behind every therapeutic product, DNA based Rx innovations would never get off the ground. No IP, no therapeutic innovation. That simple. The enormous costs demand IP protection for the innovator. The arguments for restricting patenting of human DNA must bear this key issue in mind. The so-called genetic freedom is a fuzzy concept with very negative consequences.
http://lnkd.in/8ZzNKT
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022